Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23648123 | 1.00 | POLA1 (0.69) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL8540848 | 1.00 | POLA1 (0.69) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL15720909 | 1.00 | POLA1 (0.69) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL8537214 | 0.92 | POLA1 (0.69) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL8539812 | 0.92 | POLA1 (0.69) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL3748702 | 0.91 | POLA1 (0.72) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL3748707 | 0.91 | POLA1 (0.72) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL25512701 | 0.91 | POLA1 (0.72) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL8541032 | 0.90 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL5982591 | 0.90 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| US-6864049-B1 | Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules | APPLIGENE-ONCOR S.A. (FR) | 2005-03-08 | — | — | US | claimed |
| JP-2000512843-A | — | — | 2000-10-03 | — | — | JP | claimed |
| EP-0954610-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | Appligene-Oncor S.A. (FR) | 1999-11-10 | — | — | EP | claimed |
| WO-1997049833-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | APPLIGENE-ONCOR S.A. (FR) | 1997-12-31 | — | — | WO | claimed |
| US-20240376538-A1 | PRETREATMENT METHOD FOR DNA ADDUCTOMICS SAMPLES | NATIONAL INSTITUTES OF HEALTH | 2024-11-14 | — | — | US | disclosed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | disclosed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | disclosed |
| US-20140371080-A1 | HIGH-THROUGHPUT RNA INTERACTION ASSAY | CORNELL UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014078633-A1 | METHODS FOR TREATING CANCERS HAVING BRCA2 AND PALB2 MUTATIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-6864049-B1 | Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules | APPLIGENE-ONCOR S.A. (FR) | 2005-03-08 | — | — | US | disclosed |
| EP-0954610-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | Appligene-Oncor S.A. (FR) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997049833-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | APPLIGENE-ONCOR S.A. (FR) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | POLA1 5/4885KDM4E 1953/4885PNP 1285/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | POLA1 2016/4885KDM4E 4693/4885PNP 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.